Timothy M. Mayleben

Timothy M. Mayleben, listed as senior executive, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Marinus Pharmaceuticals, Inc. and Esperion Therapeutics, Inc. Between 15 January 2016 and 7 February 2025, the trades on record add up to 8 filings.

Purchases make up the whole of the open-market record (2 purchases). The totals do not cover 2 filings with an undisclosed amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 4 share grants.

The newest entry dates from 11 February 2025: a transaction of €2,436, in Marinus Pharmaceuticals, Inc. The last purchase on record was published on 28 January 2016, which is 3,915 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.